Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 89,4 M
EBIT 2017 -150 M
Net income 2017 -166 M
Debt 2017 100 M
Yield 2017 -
Sales 2018 152 M
EBIT 2018 -113 M
Net income 2018 -117 M
Debt 2018 9,00 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 18,3x
EV / Sales2018 10,2x
Capitalization 1 532 M
More Financials
Company
Lexicon Pharmaceuticals, Inc. operates as a biopharmaceutical company which focuses on the development of breakthrough treatments for human disease.It has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications.The company was... 
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on LEXICON PHARMACEUTICALS, I
03/09 LEXICON PHARMACEUTICALS : To Report Fourth Quarter And Year End 2016 Financial R..
03/09 LEXICON PHARMACEUTICALS : FDA Approves Lexicon Drug XERMELO telotristat ethyl 25..
03/06 LEXICON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
03/03 LEXICON PHARMACEUTICALS : LXRX) Jumps on Narrower Loss
03/03 LEXICON PHARMACEUTICALS, INC. (NASDA : LXRX) Files An 8-K Results of Operations ..
03/03 LEXICON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, F..
03/03 LEXICON PHARMACEUTICALS : reports 4Q loss
03/01 HERE’S WHAT’S NEXT FOR L : LXRX) and Dynavax Technologies Corporatio..
02/28 LEXICON PHARMACEUTICALS : FDA Approves Lexicon Drug Xermelo™ (Telotristat ..
01/19 LEXICON PHARMACEUTICALS : Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 ..
More news
Sector news : Bio Therapeutic Drugs
05:01p China's Creat makes 1.2 billion euro bid for German blood plasma firm
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2015 SEEKING ALPHA'S BIOTECH WEEKLY : A Gilead Victory, Celladon Crumbles, And More
2015 Lexicon Undervalued As It Approaches A Major Event
2015 Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q1 2015 Results - Earning..
2015 Lexicon Pharmaceuticals EPS in-line, beats on revenue
2015 Lexicon Pharmaceuticals - A Diamond In The Rough?
Advertisement
Chart LEXICON PHARMACEUTICALS, I
Duration : Period :
Lexicon Pharmaceuticals, I Technical Analysis Chart | LXRX | US5288721047 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 26,3 $
Spread / Average Target 79%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & EVP-Clinical Development
Frank P. Palantoni Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICAL..12.10%1 532
AMGEN, INC.11.52%120 086
CELGENE CORPORATION7.21%96 538
GILEAD SCIENCES, INC.-6.07%87 925
REGENERON PHARMACEUTIC..7.37%41 811
ACTELION LTD24.44%30 002
More Results